Phase 2 Study of the efficacy and safety of erdafitinib in patients (pt) with bacillus Calmetter-Guerin (BCG)-unresponsive, high risk non-muscle invasive bladder cancer (HR-NMIBC) with FRFR3/2 alterations (alt) in THOR-2:cohort 2 interin analysis results

James W.F.  Catto; Ben Tran; Viraj A. Master; Morgan Roupret; Geraldine Pignot; Andrea Tubaro; Nobuaki Shimizu; Nikhil Vasdev; Jurgen Gschwend; Yohann Loriot; Hiyoyuki Nishiyama; Joan Redorta; Siamak Daneshmand; Yuji Miura; Vahid Naini; Lauren Crow; Spyros Triantos; Mahadi Baig; Gary D. Steinberg

Phase 2 Study of the efficacy and safety of erdafitinib in patients (pt) with bacillus Calmetter-Guerin (BCG)-unresponsive, high risk non-muscle invasive bladder cancer (HR-NMIBC) with FRFR3/2 alterations (alt) in THOR-2:cohort 2 interin analysis results

James W.F. Catto, Ben Tran, Viraj A. Master, Morgan Roupret, Geraldine Pignot, Andrea Tubaro, Nobuaki Shimizu, Nikhil Vasdev, Jurgen Gschwend, Yohann Loriot, Hiyoyuki Nishiyama, Joan Redorta, Siamak Daneshmand, Yuji Miura, Vahid Naini, Lauren Crow, Spyros Triantos, Mahadi Baig, Gary D. Steinberg

Research output: Contribution to journal › Article

Original language	English
Journal	The Lancet. Oncology
Publication status	In preparation - 11 Oct 2022

Embargoed Document

THOR-2 Cohort 2 Abstract Submisison Proof ASCO-GU 2023_11Oct22
Other version, 1.02 MB

Cite this

Catto, J. W. F., Tran, B., Master, V. A., Roupret, M., Pignot, G., Tubaro, A., Shimizu, N., Vasdev, N., Gschwend, J., Loriot, Y., Nishiyama, H., Redorta, J., Daneshmand, S., Miura, Y., Naini, V., Crow, L., Triantos, S., Baig, M., & Steinberg, G. D. (2022). Phase 2 Study of the efficacy and safety of erdafitinib in patients (pt) with bacillus Calmetter-Guerin (BCG)-unresponsive, high risk non-muscle invasive bladder cancer (HR-NMIBC) with FRFR3/2 alterations (alt) in THOR-2:cohort 2 interin analysis results. Manuscript in preparation.

@article{faac4e6220514b519e977639e8523b60,

title = "Phase 2 Study of the efficacy and safety of erdafitinib in patients (pt) with bacillus Calmetter-Guerin (BCG)-unresponsive, high risk non-muscle invasive bladder cancer (HR-NMIBC) with FRFR3/2 alterations (alt) in THOR-2:cohort 2 interin analysis results",

author = "Catto, {James W.F.} and Ben Tran and Master, {Viraj A.} and Morgan Roupret and Geraldine Pignot and Andrea Tubaro and Nobuaki Shimizu and Nikhil Vasdev and Jurgen Gschwend and Yohann Loriot and Hiyoyuki Nishiyama and Joan Redorta and Siamak Daneshmand and Yuji Miura and Vahid Naini and Lauren Crow and Spyros Triantos and Mahadi Baig and Steinberg, {Gary D.}",

year = "2022",

month = oct,

day = "11",

language = "English",

journal = "The Lancet. Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

}

Catto, JWF, Tran, B, Master, VA, Roupret, M, Pignot, G, Tubaro, A, Shimizu, N, Vasdev, N, Gschwend, J, Loriot, Y, Nishiyama, H, Redorta, J, Daneshmand, S, Miura, Y, Naini, V, Crow, L, Triantos, S, Baig, M & Steinberg, GD 2022, 'Phase 2 Study of the efficacy and safety of erdafitinib in patients (pt) with bacillus Calmetter-Guerin (BCG)-unresponsive, high risk non-muscle invasive bladder cancer (HR-NMIBC) with FRFR3/2 alterations (alt) in THOR-2:cohort 2 interin analysis results', The Lancet. Oncology.

Phase 2 Study of the efficacy and safety of erdafitinib in patients (pt) with bacillus Calmetter-Guerin (BCG)-unresponsive, high risk non-muscle invasive bladder cancer (HR-NMIBC) with FRFR3/2 alterations (alt) in THOR-2:cohort 2 interin analysis results. / Catto, James W.F. ; Tran, Ben; Master, Viraj A. et al.

In: The Lancet. Oncology, 11.10.2022.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Phase 2 Study of the efficacy and safety of erdafitinib in patients (pt) with bacillus Calmetter-Guerin (BCG)-unresponsive, high risk non-muscle invasive bladder cancer (HR-NMIBC) with FRFR3/2 alterations (alt) in THOR-2:cohort 2 interin analysis results

AU - Catto, James W.F.

AU - Tran, Ben

AU - Master, Viraj A.

AU - Roupret, Morgan

AU - Pignot, Geraldine

AU - Tubaro, Andrea

AU - Shimizu, Nobuaki

AU - Vasdev, Nikhil

AU - Gschwend, Jurgen

AU - Loriot, Yohann

AU - Nishiyama, Hiyoyuki

AU - Redorta, Joan

AU - Daneshmand, Siamak

AU - Miura, Yuji

AU - Naini, Vahid

AU - Crow, Lauren

AU - Triantos, Spyros

AU - Baig, Mahadi

AU - Steinberg, Gary D.

PY - 2022/10/11

Y1 - 2022/10/11

M3 - Article

JO - The Lancet. Oncology

JF - The Lancet. Oncology

SN - 1470-2045

ER -